BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

612 related articles for article (PubMed ID: 21294526)

  • 1. Interaction of mesoporous silica nanoparticles with human red blood cell membranes: size and surface effects.
    Zhao Y; Sun X; Zhang G; Trewyn BG; Slowing II; Lin VS
    ACS Nano; 2011 Feb; 5(2):1366-75. PubMed ID: 21294526
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of PEGylation of mesoporous silica nanoparticles on nonspecific binding of serum proteins and cellular responses.
    He Q; Zhang J; Shi J; Zhu Z; Zhang L; Bu W; Guo L; Chen Y
    Biomaterials; 2010 Feb; 31(6):1085-92. PubMed ID: 19880176
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mimicking red blood cell lipid membrane to enhance the hemocompatibility of large-pore mesoporous silica.
    Roggers RA; Joglekar M; Valenstein JS; Trewyn BG
    ACS Appl Mater Interfaces; 2014 Feb; 6(3):1675-81. PubMed ID: 24417657
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impacts of mesoporous silica nanoparticle size, pore ordering, and pore integrity on hemolytic activity.
    Lin YS; Haynes CL
    J Am Chem Soc; 2010 Apr; 132(13):4834-42. PubMed ID: 20230032
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mesoporosity and functional group dependent endocytosis and cytotoxicity of silica nanomaterials.
    Tao Z; Toms BB; Goodisman J; Asefa T
    Chem Res Toxicol; 2009 Nov; 22(11):1869-80. PubMed ID: 19817448
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of size on the cellular endocytosis and controlled release of mesoporous silica nanoparticles for intracellular delivery.
    Gan Q; Dai D; Yuan Y; Qian J; Sha S; Shi J; Liu C
    Biomed Microdevices; 2012 Apr; 14(2):259-70. PubMed ID: 22124885
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of surface functionalization of MCM-41-type mesoporous silica nanoparticles on the endocytosis by human cancer cells.
    Slowing I; Trewyn BG; Lin VS
    J Am Chem Soc; 2006 Nov; 128(46):14792-3. PubMed ID: 17105274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vivo biodistribution and urinary excretion of mesoporous silica nanoparticles: effects of particle size and PEGylation.
    He Q; Zhang Z; Gao F; Li Y; Shi J
    Small; 2011 Jan; 7(2):271-80. PubMed ID: 21213393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A mesoporous silica nanoparticle with charge-convertible pore walls for efficient intracellular protein delivery.
    Park HS; Kim CW; Lee HJ; Choi JH; Lee SG; Yun YP; Kwon IC; Lee SJ; Jeong SY; Lee SC
    Nanotechnology; 2010 Jun; 21(22):225101. PubMed ID: 20453291
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Poly-L-lysine functionalized large pore cubic mesostructured silica nanoparticles as biocompatible carriers for gene delivery.
    Hartono SB; Gu W; Kleitz F; Liu J; He L; Middelberg AP; Yu C; Lu GQ; Qiao SZ
    ACS Nano; 2012 Mar; 6(3):2104-17. PubMed ID: 22385282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of the shape of mesoporous silica nanoparticles on cellular uptake and cell function.
    Huang X; Teng X; Chen D; Tang F; He J
    Biomaterials; 2010 Jan; 31(3):438-48. PubMed ID: 19800115
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesoporous silica nanoparticles improve magnetic labeling efficiency in human stem cells.
    Liu HM; Wu SH; Lu CW; Yao M; Hsiao JK; Hung Y; Lin YS; Mou CY; Yang CS; Huang DM; Chen YC
    Small; 2008 May; 4(5):619-26. PubMed ID: 18491363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Internalization of mesoporous silica nanoparticles induces transient but not sufficient osteogenic signals in human mesenchymal stem cells.
    Huang DM; Chung TH; Hung Y; Lu F; Wu SH; Mou CY; Yao M; Chen YC
    Toxicol Appl Pharmacol; 2008 Sep; 231(2):208-15. PubMed ID: 18519141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Model system to study the influence of aggregation on the hemolytic potential of silica nanoparticles.
    Thomassen LC; Rabolli V; Masschaele K; Alberto G; Tomatis M; Ghiazza M; Turci F; Breynaert E; Martra G; Kirschhock CE; Martens JA; Lison D; Fubini B
    Chem Res Toxicol; 2011 Nov; 24(11):1869-75. PubMed ID: 21928780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mesoporous silica nanoparticles for the improved anticancer efficacy of cis-platin.
    Lin CH; Cheng SH; Liao WN; Wei PR; Sung PJ; Weng CF; Lee CH
    Int J Pharm; 2012 Jun; 429(1-2):138-47. PubMed ID: 22465413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PEG-templated mesoporous silica nanoparticles exclusively target cancer cells.
    Morelli C; Maris P; Sisci D; Perrotta E; Brunelli E; Perrotta I; Panno ML; Tagarelli A; Versace C; Casula MF; Testa F; Andò S; Nagy JB; Pasqua L
    Nanoscale; 2011 Aug; 3(8):3198-207. PubMed ID: 21725561
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemolytic properties of synthetic nano- and porous silica particles: the effect of surface properties and the protection by the plasma corona.
    Shi J; Hedberg Y; Lundin M; Odnevall Wallinder I; Karlsson HL; Möller L
    Acta Biomater; 2012 Sep; 8(9):3478-90. PubMed ID: 22522009
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards multifunctional, targeted drug delivery systems using mesoporous silica nanoparticles--opportunities & challenges.
    Rosenholm JM; Sahlgren C; Lindén M
    Nanoscale; 2010 Oct; 2(10):1870-83. PubMed ID: 20730166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biocompatibility of mesoporous silica nanoparticles.
    Asefa T; Tao Z
    Chem Res Toxicol; 2012 Nov; 25(11):2265-84. PubMed ID: 22823891
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mesoporous silica nanoparticles for intracellular controlled drug delivery.
    Vivero-Escoto JL; Slowing II; Trewyn BG; Lin VS
    Small; 2010 Sep; 6(18):1952-67. PubMed ID: 20690133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.